Details

Autor(en) / Beteiligte

• Margalit, Ofer
• Shacham-Shmueli, Einat
• Strauss, Gal
• Yang, Yu-Xiao
• Lawrence, Yaacov R.
• Ben Nun, Alon
• Levy, Idan
• Reiss, Kim A.
• Golan, Talia
• Halpern, Naama
• Aderka, Dan
• Giantonio, Bruce
• Mamtani, Ronac
• Boursi, Ben

Titel

Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma

Ist Teil von

• Cancer investigation, 2023-09, Vol.41 (8), p.734-738

Erscheinungsjahr

2023

Quelle

Access via Taylor & Francis

Beschreibungen/Notizen

• Current guidelines recommend that clinically staged T1N0 esophageal cancers are to be referred to surgery or endoscopic resection. Using the National Cancer Database, we identified 733 individuals with clinically staged T1N0 esophageal carcinoma, who underwent upfront surgery and did not receive any prior treatment. We assessed upstaging, which was defined as ≥ T2 disease or positive lymph nodes. Poorly differentiated adenocarcinomas were associated with upstaging, whereas squamous cell carcinomas were not. Specifically, the percentage of upstaging among individuals with clinically staged T1b and poorly differentiated tumor was 33.8%. Therefore, clinically staged T1bN0 poorly differentiated esophageal adenocarcinomas are at high risk for upstaging following surgery.